In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it ...
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
In a closely watched appeal, the U.S. Court of Appeals for the First Circuit ruled on February 18 that to satisfy the causation requirement in ...
The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal ...
On February 18, 2025, the First Circuit Court of Appeals issued its decision in U.S. v. Regeneron Pharmaceuticals, ruling ...
9h
Zacks.com on MSNPharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & MoreThis week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...
Hosted on MSN10h
2 Healthcare Stocks with Big Upside and 1 to SkipHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But ...
Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results